Celecoxib effectively reprograms the immunosuppressive tumor microenvironment by targeting the COX-2/PGE2 axis, inhibiting immunosuppressive cells (Tregs, MDSCs, M2 macrophages) while enhancing CD8+ T cell infiltration and activity. The gene discussed is CD8A; the disease is neoplasm.